Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IDT Australia Limited (IDT.AX)
Boronia, VIC, AU
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -7.50% | -26.00% | -30.19% | -27.45% | -64.76% | -56.83% | -88.49% | -87.34% | -97.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+49.4% ★ Q4'25: +69.7% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-21.9% Q4'25: +71.6% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-49.3% Q4'25: +7.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-37.4% Q4'25: -9.1% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-26.3% Q4'25: -12.5% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+22.7% Q4'25: +21.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.59× Q4'25: -5.56× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.72M
est: 16.56M (-5.1%)
|
7.61M
est: 18.18M (-58.1%)
|
9.54M
est: 10.06M (-5.2%)
|
12.89M
est: 14.10M (-8.6%)
|
12.13M
est: 19.50M (-37.8%)
|
14.10M
est: 20.90M (-32.5%)
|
15.99M
est: 20.64M (-22.5%)
|
12.11M
est: 14.00M (-13.5%)
|
6.94M
est: 6.94M (+0.0%)
|
13.23M
est: 13.50M (-2.0%)
|
19.77M
est: 22.80M (-13.3%)
|
27.40M
27.40M – 27.40M
+20.2% YoY
|
32.00M
32.00M – 32.00M
+16.8% YoY
|
| EBITDA |
-929.0K
est: -5.33M (+82.6%)
|
-3.57M
est: -5.85M (+38.9%)
|
-12.67M
est: -3.24M (-291.4%)
|
-15.92M
est: -4.53M (-251.1%)
|
-3.58M
est: -6.27M (+43.0%)
|
721.0K
est: -6.72M (+110.7%)
|
2.75M
est: -6.64M (+141.4%)
|
-340.0K
est: -4.50M (+92.4%)
|
-8.83M
est: -2.23M (-296.1%)
|
-5.56M
est: -4.34M (-28.2%)
|
-6.54M
est: -7.33M (+10.8%)
|
-8.81M
-8.81M – -8.81M
-20.2% YoY
|
-10.29M
-10.29M – -10.29M
-16.8% YoY
|
| EBIT |
-3.17M
est: -6.49M (+51.2%)
|
-5.66M
est: -7.13M (+20.6%)
|
-7.21M
est: -3.94M (-82.8%)
|
-18.54M
est: -5.53M (-235.6%)
|
-6.10M
est: -7.64M (+20.2%)
|
-1.25M
est: -8.19M (+84.8%)
|
966.0K
est: -8.09M (+111.9%)
|
-1.88M
est: -5.49M (+65.8%)
|
-9.89M
est: -2.72M (-263.8%)
|
-6.49M
est: -5.29M (-22.6%)
|
-7.40M
est: -8.94M (+17.2%)
|
-10.74M
-10.74M – -10.74M
-20.2% YoY
|
-12.54M
-12.54M – -12.54M
-16.8% YoY
|
| Net Income |
-2.99M
est: -7.35M (+59.3%)
|
-4.01M
est: -1.98M (-102.5%)
|
-773.0K
est: 8.18M (-109.4%)
|
-16.98M
est: -7.91M (-114.7%)
|
-6.08M
est: -3.75M (-62.4%)
|
-1.92M
est: -4.16M (+53.9%)
|
2.10M
est: -4.60M (+145.7%)
|
-1.16M
est: -4.58M (+74.7%)
|
-8.50M
est: -14.49M (+41.3%)
|
-5.41M
est: -7.49M (+27.8%)
|
-8.06M
est: 2.14M (-477.3%)
|
2.99M
2.99M – 2.99M
+40.0% YoY
|
5.98M
5.98M – 5.98M
+100.0% YoY
|
| SGA |
9.83M
est: 13.28M (-25.9%)
|
12.07M
est: 14.58M (-17.2%)
|
12.64M
est: 8.07M (+56.6%)
|
4.31M
est: 11.31M (-61.9%)
|
12.56M
est: 15.63M (-19.7%)
|
7.09M
est: 16.76M (-57.7%)
|
7.20M
est: 16.55M (-56.5%)
|
6.68M
est: 11.22M (-40.5%)
|
9.19M
est: 5.56M (+65.3%)
|
12.00M
est: 10.82M (+10.9%)
|
15.30M
est: 18.28M (-16.3%)
|
21.97M
21.97M – 21.97M
+20.2% YoY
|
25.66M
25.66M – 25.66M
+16.8% YoY
|
| EPS |
-0.02
est: -0.02 (-27.9%)
|
-0.02
est: 0.00 (-323.4%)
|
-0.06
est: 0.02 (-406.1%)
|
-0.07
est: -0.02 (-272.9%)
|
-0.03
est: -0.01 (-189.8%)
|
-0.01
est: -0.01 (+16.8%)
|
0.01
est: -0.01 (+181.8%)
|
0.00
est: -0.01 (+55.2%)
|
-0.03
est: -0.03 (0.0%)
|
-0.02
est: -0.02 (+11.6%)
|
-0.02
est: 0.01 (-478.0%)
|
0.01
0.01 – 0.01
+40.0% YoY
|
0.01
0.01 – 0.01
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jim Sosic | Chief Operating Officer | 302.7K | male |
| Michael Thompson | Director of Commercial & Business Development | 227.3K | male |
| Paula Coutts | Director of People & Safety | 214.9K | female |
| Robert Caunce | Director of Quality | 205.3K | male |
| Malika Perera | Head of Finance | — | male |
| Mark Andrew Licciardo FCIS FGIA GAICD | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDT.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
